Author

C. W. McNamara

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Chen· 2 shared M. V. Hull· 2 shared P. G. Schultz· 2 shared A. K. Chatterjee· 1 shared A. K. Gupta· 1 shared A. K. Woods· 1 shared B. C. VanderVen· 1 shared B. Qin· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

E. Chen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivAug 3, 2021

Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis

K. M. Wilburn, C. R. Montague, B. Qin…·B. C. VanderVen

This paper identifies a small molecule agonist of Mtb adenylyl cyclase Rv1625c that inhibits cholesterol utilization and disrupts Mtb pathogenesis in mice.

DOI 10.1371/journal.ppat.1009862

experimental assaydrug response / drug discovery

𝕏 PostBluesky

MicrobiologyNature CommunicationsPeer-reviewedJun 3, 2021

Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19

M. A. Bakowski, N. Beutler, E. Chen…·T. F. Rogers

The paper identifies 66 compounds that inhibit SARS-CoV-2 replication and 24 that synergize with remdesivir, suggesting potential oral drug repositioning candidates for COVID-19.

DOI 10.1038/s41467-021-23328-0

humanproteomics

𝕏 PostBluesky

MicrobiologybioRxivDec 11, 2019

High-throughput screening of the ReFRAME library identifies potential drug repurposing candidates for Trypanosoma cruzi

J. A. Bernatchez, E. Chen, M. V. Hull…·J. L. Siqueira-Neto

The paper screens 12,000 compounds from the ReFRAME library against Trypanosoma cruzi, identifying 7 with potent in vitro activity and therapeutic index ≥10.

DOI 10.3390/microorganisms8040472

experimental assaydrug response / drug discovery

𝕏 PostBluesky